News >

Mantle Cell Lymphoma Options Expand, With CAR-T on the Horizon

Nichole Tucker
Published: Thursday, Aug 08, 2019

Kieron Dunleavy, MD

Kieron Dunleavy, MD

Novel agents, including BTK and BCL-2 inhibitors have dramatically improved the treatment paradigm in mantle call lymphoma (MCL), explained Kieron Dunleavy, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x